

**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

1 pp. 170  
Right  
14

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/020,393 02/09/98 SIMS P OMRF-170

0222/0413

PATREA L PABST  
ARNALL GOLDEN & GREGORY  
2800 W PEACHTREE STREET  
ATLANTA GA 30309-3450

NOT ASSIGNED

DATE MAILED: 1998

04/13/98

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER:

**APPLICANT MUST PROVIDE:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☐ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

5-13-98  
JSH  
4-21-98

BEST AVAILABLE COPY

0300 / Box  
Sequence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter J. Sims

Serial No: 09/020,393



Art Unit: Not yet assigned

Filed: February 9, 1998

Examiner: Not yet assigned

For: *Compositions and Methods to Inhibit Formation of the C5b-9 Complex of Complement*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES, AMENDMENT  
AND DECLARATION UNDER 37 C.F.R. §1.821(f)**

Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures mailed on April 13, 1998, in the above-identified application, applicants enclose a 3½" diskette containing a computer-readable form of the Sequence Listing. Applicants also enclose a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Since the specification as filed included a paper copy of the Sequence Listing, no paper copy of the Sequence Listing is provided with this Response. It is believed that no fee is due with this response. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

U.S.S.N.: 09/020,393


Filed: February 9, 1998

For: *Compositions and Methods to Inhibit Formation of the C5b-9 Complex of Complement*  
Response to Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,  
Amendment and Declaration under 37 C.F.R. §1.821 (f)

### **CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)**

---

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Teresa R. Spratt

Date: April 24, 1998